Entering text into the input field will update the search result below

NeuroMetrix submits FDA De Novo request for neurostimulation device Quell

Oct. 07, 2021 12:12 AM ETNeuroMetrix, Inc. (NURO) StockBy: SA News Team

Human Body Joint Pain

wildpixel/iStock via Getty Images

  • NeuroMetrix (NASDAQ:NURO) has submitted a De Novo request to the FDA for Quell as a prescription treatment for the symptoms of fibromyalgia in adults.
  • Shares rose 14.7% after-hours. Yesterday's close was $8.62.
  • Fibromyalgia is a chronic pain

Recommended For You

More Trending News

About NURO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NURO--
NeuroMetrix, Inc.